Fairfield, Bush & Co. Editas Medicine, Inc. Transaction History

Fairfield, Bush & Co.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 09, 2022	SELL	$26.55 - $40.57 $345,150 - $527,410	-13,000 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$39.27 - $72.94 $510,510 - $948,220	13,000 New	13,000 $534,000
Q2 2021 Aug 02, 2021	SELL	$31.29 - $56.64 $187,740 - $339,840	-6,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$27.07 - $84.35 $162,420 - $506,099	6,000 New	6,000 $420,000

225

54.2M

412K

355K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $132M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Fairfield, Bush & Co., based on Form 13F filings with the SEC.

Stay updated on Fairfield, Bush & Co. with notifications on news.